Clinical medicine profile
Bambuterol
Beta-2 adrenergic agonist (bronchodilator)
- Route
- INHALATION / ORAL / NEB / IV (rare)
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity.
- LABA monotherapy in asthma is contraindicated — always with ICS.
Precautions
- Paradoxical bronchospasm.
- Hypokalaemia with high dose/nebs especially with steroids/diuretics/xanthines.
- CV disease: tachycardia/arrhythmia risk.
- Thyrotoxicosis caution.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Adults: 10mg OD in the evening and may be increased to 20mg after 1-2 weeks.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Low for inhaled; monitor electrolytes if continuous nebs.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Low clinical concern for inhaled therapy.
Use, effects & interactions
Indications
- Bronchospasm in asthma, bronchitis, chronic bronchitis, ephysema, and bronchiectasis.
- Clinical selection for Bambuterol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Beta-2 adrenergic agonist (bronchodilator).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Tachycardia, skeletal muscle cramp, palpitation, headaches, severe emotional disturbances, resistance after prolonged use, acidosis, GI disturbances, hypokaleamia, sweat
Drug interactions
Open multi-drug checker ↗- It is an oral pro-drug of terbutaline with a prolonged duration of bronchodilator action that allows once-daily administration.
- It is an inactive site-specific pro-drug that delivers terbutaline only to the lungs.
Mechanism & disposition
It is a beta 2 agonist that is an oral pro-drug of terbutaline with a prolonged duration of bronchodilator action that allows once- daily administration.
Read complete mechanism
It is a beta 2 agonist that is an oral pro-drug of terbutaline with a prolonged duration of bronchodilator action that allows once- daily administration. It is an inactive site-specific pro-drug that delivers terbutaline only to the lungs.
Minutes (SABA)
3–6 h SABA; 12 h LABA
INHALATION / ORAL / NEB / IV (rare)
causes tremor/tachycardia. Hepatic
of many agents.
Pregnancy, lactation & diet
Inhaled salbutamol widely used; uncontrolled asthma risk > drug risk.
Inhaled therapy generally compatible.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.